A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1103-1107

  Mascarenhas, Leo ^a,b   Malogolowkin, Marcio ^c   Armenian, Saro H ^d   Sposto, Richard ^a,b   Venkatramani, Rajkumar ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Children; Doxorubicin; Oxaliplatin; Phase I; Recurrent; Refractory; Relapsed; Solid tumors

Indexed keywords

DOXORUBICIN; OXALIPLATIN;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EXPOSURE; DYSESTHESIA; FEMALE; FEVER; GERM CELL TUMOR; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LARGE CELL NEUROENDOCRINE CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; YOUNG ADULT;

EID: 84878217873     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24471     Document Type: Article

References (28)

1. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-2011.
2. Malogolowkin MH, Katzenstein HM, Krailo M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 2008;26:2379-2383.
3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
4. Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588-8596.
5. Cvitkovic E. Ongoing and unsaid on oxaliplatin: The hope. Br J Cancer 1998; 77: 8-11.
6. Dunn TA, Schmoll HJ, Grünwald V, et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997;15:109-114.
7. Fukuda M, Ohe Y, Kanzawa F, et al. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995;15:393-398.
8. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988;48:9-13.
9. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-5976.
10. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-1865.
11. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
12. Spunt SL, Freeman BB, Billups CA, et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol 2007;25:2274-2280.
13. Beaty O, III, Berg S, Blaney S, et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2010;55:440-445.
14. Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: A pediatric brain tumor consortium study. Cancer 2006;107:2291-2297.
15. McGregor LM, Spunt SL, Furman WL, et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: A children's oncology group study. Cancer 2009;115:1765-1775.
16. Geoerger B, Doz F. Gentet J-C, et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol 2008;26:4394-4400.
17. Evans AE, Baehner RL. Chard RL, Jr., et al. Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors. Cancer Chemother Rep 1974;58:671-676.
18. Pratt CB, Shanks EC. Doxorubicin in treatment of malignant solid tumors in children. Am J Dis Child 1974;127:534-536.
19. Recchia F, De Filippis S, Saggio G, et al. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs 2003;14:633-638.
20. Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:929-935.
21. Nicoletto MO, Falci C, Pianalto D, et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol 2006;100:318-323.
22. Recchia F, Candeloro G, Guerriero G, et al. Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier. Anticancer Drugs 2010;21:559-564.
23. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012;30:1429-1437.
24. McGregor LM, Spunt SL, Santana VM, et al. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer 2009;115:655-664.
25. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-1332.
26. Macy ME, Duncan T, Whitlock J, et al. A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer 2013;60:230-236.
27. Díaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 1998;9:105-108.
28. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.